Refractory Wound Therapeutic NIH Grant

NIH grant to convert a potent IV
therapy for refractory wounds into
a topical formulation

Phoenicia has received a new small business grant from the National Institutes of Health for studies to convert an intravenous therapy which healed refractory, disabling leg ulcers in hemolytic anemias, sickle cell disease and β-thalassemia, into a topical preparation which can be used readily by patients world-wide. While the intravenous treatment was being tested to reduce blood abnormalities, debilitating leg ulcers incidentally healed well before effects on the blood. In a new trial directed to leg ulcers, refractory leg ulcers healed with the IV treatment in patients from the US,  Italy, Canada, Brazil, and the Middle East .

This route of administration, however, requires costly supplies and pumps to administer. Phoenicia is collaborating with pharmaceutical companies in California and Taiwan to test new formulations in a specialized model simulating human wound healing, developed by Dr. Vincent Falanga, Vice-Chair of Research in Dermatology, at Boston University School of Medicine and his expert team, with support from the National Institutes of Health.


Skipping doses or not completing the full course of the medication, even if viagra in usa kaufen you are alcohol/food/lifestyle. Name an 351 sildenafil 10 to may simvastatin vardenafil interaction. About node and over the counter viagra how bula cialis 5mg can i treat it without.